Tommy joined Sofinnova as a Senior Analyst in 2014. He focuses on both private and public investments in therapeutics companies and has been involved in the firm’s investments in ASND, Audentes, MCRB,NTRA, and EDGE. He is responsible for advising on the management of the firm’s public equities portfolio.
Prior to joining Sofinnova, Tommy was a Principal and Analyst on the healthcare investment team at Jennison Associates. He also previously covered biotech stocks on the sell-side at a number of investment banks (including Guggenheim, Jefferies, and Piper Jaffray), ultimately as a Director and Senior Biotech Analyst. Prior to Wall Street, Tommy trained in internal medicine and a cardiology fellowship at New York-Presbyterian Hospital, where he was awarded a New York Academy of Medicine’s Glorney-Raisbeck Fellowship in Cardiovascular Disease.
Tommy received his MD and PhD in Molecular and Cellular Biology from the Tri-Institutional program of Cornell Medical College/ Memorial Sloan-Kettering Cancer Center/ Rockefeller University through the NIH Medical Scientist Training Program. He graduated with a BA in Chemistry magna cum laude from Harvard University. Tommy has been lead author in a number of scientific publications and has served as an adjunct faculty at Stanford University since 2015.
Assistant: Veronica Castaneda